Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645086 | 0.99 | HDAC3 (0.44) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1645116 | 0.91 | MAP3K5 (0.44) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1645140 | 0.91 | PTGER4 (0.44) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1644375 | 0.89 | HDAC3 (0.43) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1284412 | 0.89 | HDAC3 (0.40) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1285679 | 0.89 | HDAC3 (0.40) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1645194 | 0.89 | HDAC3 (0.41) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1644203 | 0.88 | HRH3 (0.42) | HDAC3HDAC2SMN1; SMN2HRH3MCHR1 | |
| SCHEMBL1285305 | 0.88 | HDAC3 (0.41) | MAPTTP53HDAC3HDAC2SMN1; SMN2 | |
| SCHEMBL1285304 | 0.88 | HDAC3 (0.41) | MAPTTP53HDAC3HDAC2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MAPT 3251/4885TP53 3973/4885HDAC3 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.